Back to Search
Start Over
Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts.
- Source :
- Transplantation, 85 (2
- Publication Year :
- 2008
-
Abstract
- One year survival of islet cell grafts has been reproducibly achieved under combination immune therapy including tacrolimus (TAC). However, the use of TAC causes beta-cell and renal toxicity. Because sirolimus (SIR) monotherapy was successful in kidney transplantation under antithymocyte globulin (ATG), we undertook a pilot study comparing SIR monotherapy with SIR-TAC combination therapy.<br />Clinical Trial<br />Comparative Study<br />Journal Article<br />Research Support, Non-U.S. Gov't<br />SCOPUS: ar.j<br />info:eu-repo/semantics/published
Details
- Database :
- OAIster
- Journal :
- Transplantation, 85 (2
- Notes :
- No full-text files, English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.ocn837147618
- Document Type :
- Electronic Resource